Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BL-B01D1 + PD-1/VEGF Bispecific Antibody in 1L Non-squamous NSCLC
NCT07739186Phase 3Not yet recruiting
- Sponsor
- Biokin Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of izalontamab brengitecan in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (3 arms), sponsored by Biokin Pharmaceutical. Primary endpoints: Treatment Emergent Adverse Event at 24 months, Objective Response Rate at 24 months and 2 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
izalontamab brengitecan
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07739186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07739186.